VANGUARD GROUP INC - KARYOPHARM THERAPEUTICS INC ownership

KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 54 filers reported holding KARYOPHARM THERAPEUTICS INC in Q4 2013. The put-call ratio across all filers is - and the average weighting 0.6%.

Quarter-by-quarter ownership
VANGUARD GROUP INC ownership history of KARYOPHARM THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$11,818,705
-24.0%
8,819,929
+1.6%
0.00%
Q2 2023$15,544,589
-46.7%
8,684,128
+15.7%
0.00%
-100.0%
Q1 2023$29,189,922
+65.2%
7,503,836
+44.4%
0.00%
Q4 2022$17,671,507
-32.8%
5,197,502
+8.0%
0.00%
-100.0%
Q3 2022$26,282,000
+38.0%
4,813,399
+14.0%
0.00%0.0%
Q2 2022$19,041,000
-34.8%
4,221,980
+6.6%
0.00%0.0%
Q1 2022$29,190,000
+35.2%
3,960,708
+17.9%
0.00%
Q4 2021$21,597,000
+1.9%
3,358,807
-7.8%
0.00%
-100.0%
Q3 2021$21,201,000
-43.1%
3,642,699
+0.8%
0.00%0.0%
Q2 2021$37,290,000
-0.3%
3,613,336
+1.6%
0.00%0.0%
Q1 2021$37,414,000
-30.6%
3,556,453
+2.2%
0.00%
-50.0%
Q4 2020$53,877,000
+7.1%
3,480,399
+1.1%
0.00%0.0%
Q3 2020$50,284,000
-25.5%
3,444,065
-3.4%
0.00%0.0%
Q2 2020$67,501,000
+8.2%
3,564,005
+9.7%
0.00%
-33.3%
Q1 2020$62,403,000
+17.7%
3,248,459
+17.4%
0.00%
+50.0%
Q4 2019$53,023,000
+100.8%
2,765,891
+0.8%
0.00%
+100.0%
Q3 2019$26,402,000
+47.7%
2,744,561
-8.0%
0.00%0.0%
Q2 2019$17,874,000
+17.1%
2,983,862
+14.1%
0.00%0.0%
Q1 2019$15,267,000
-5.8%
2,614,272
+51.2%
0.00%0.0%
Q4 2018$16,199,000
-60.6%
1,728,887
-28.3%
0.00%
-50.0%
Q3 2018$41,092,000
-3.0%
2,412,882
-3.2%
0.00%0.0%
Q2 2018$42,360,000
+63.0%
2,493,214
+28.8%
0.00%
+100.0%
Q1 2018$25,981,000
+50.2%
1,936,043
+7.5%
0.00%0.0%
Q4 2017$17,293,000
-11.0%
1,801,391
+1.8%
0.00%0.0%
Q3 2017$19,431,000
+32.4%
1,769,666
+9.1%
0.00%0.0%
Q2 2017$14,675,000
-7.6%
1,621,420
+31.1%
0.00%0.0%
Q1 2017$15,880,000
+49.9%
1,236,762
+9.8%
0.00%0.0%
Q4 2016$10,591,000
+23.5%
1,126,669
+27.8%
0.00%0.0%
Q3 2016$8,578,000
+56.6%
881,605
+8.0%
0.00%
Q2 2016$5,478,000
-10.8%
816,444
+18.5%
0.00%
Q1 2016$6,144,000
-33.9%
688,730
-1.9%
0.00%
-100.0%
Q4 2015$9,302,000
-36.7%
702,058
-49.7%
0.00%0.0%
Q3 2015$14,706,000
-22.9%
1,396,522
+99.3%
0.00%0.0%
Q2 2015$19,067,000
+10.8%
700,716
+24.7%
0.00%0.0%
Q1 2015$17,204,000
+10.6%
562,049
+35.2%
0.00%0.0%
Q4 2014$15,559,000
+16.8%
415,689
+9.0%
0.00%0.0%
Q3 2014$13,319,000
-3.5%
381,197
+28.6%
0.00%0.0%
Q2 2014$13,798,000
+211.1%
296,407
+106.4%
0.00%
Q1 2014$4,435,000
+147.1%
143,596
+83.3%
0.00%
Q4 2013$1,795,00078,3370.00%
Other shareholders
KARYOPHARM THERAPEUTICS INC shareholders Q4 2013
NameSharesValueWeighting ↓
Consonance Capital Management LP 7,180,700$137,941,00010.27%
Palo Alto Investors LP 4,299,901$82,601,0006.92%
Fairmount Funds Management LLC 562,351$10,803,0006.55%
Avoro Capital Advisors LLC 7,000,000$134,470,0004.54%
Pinz Capital Management, LP 8,820$1,694,0004.44%
Birchview Capital, LP 148,000$2,843,0002.52%
Elk Creek Partners, LLC 699,951$13,446,0002.31%
Parkman Healthcare Partners LLC 215,802$4,146,0001.92%
EAM Global Investors LLC 136,402$2,620,0001.53%
SPHERA FUNDS MANAGEMENT LTD. 550,000$10,566,0001.32%
View complete list of KARYOPHARM THERAPEUTICS INC shareholders